Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official Title: A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo.
In Brief: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
Ages Eligible: 18 Years to 70 Years
Start Date: September 25, 2019
Completion Date (estimated): July 2020
Status: Active, recruiting
- ClinicalTrials.gov: NCT04103060
- Other Study ID Numbers: DMVT-502-2101
Location: Dermavant Investigational Site: Worcester, Massachusetts, United States, 01605
Contact: To learn more about this study, you or your doctor may contact Dermavant Sciences by phone +1-480-666-0844 or email email@example.com. Please refer to this study by its ClinicalTrials.gov identifier (NCT number)
- What tests should be done?
A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...
- What are risks of oral and topical corticosteroids?
Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...
- Is there a special diet for vitiligo?
In short, no. Some people find that certain foods may worsen their vitiligo symptoms or that others may improve their skin condition. We found no scientific evidence that a sp...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.